


Pharmaceuticals & Biotechnology | Small Cap
Orchid Pharma Ltd demonstrates a mixed financial performance. The company shows some strength in solvency, driven by a solid equity position. Growth is fueled by operating profit and asset increases. Profitability is supported by a good return on capital employed and return on assets. However, liquidity is a significant concern due to poor current, quick, and cash ratios. Efficiency is also a trouble area, as key turnover ratios are low. Financial ratios are hindered by low earnings per share and book value. While coverage is reasonable, it is mainly due to interest coverage rather than equity dividend coverage. The company needs to address its liquidity and efficiency challenges to ensure long-term sustainability and growth.
Orchid Pharma Ltd demonstrates a mixed financial performance. The company shows some strength in solvency, driven by a solid equity position. Growth is fueled by operating profit and asset increases. Profitability is supported by a good return on capital employed and return on assets. However, liquidity is a significant concern due to poor current, quick, and cash ratios. Efficiency is also a trouble area, as key turnover ratios are low. Financial ratios are hindered by low earnings per share and book value. While coverage is reasonable, it is mainly due to interest coverage rather than equity dividend coverage. The company needs to address its liquidity and efficiency challenges to ensure long-term sustainability and growth.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
111.96
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
246.31
P/B RATIO
3.93
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
5.81
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
71.86
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹997.55 as on Aug 6, 2026.
The company shows good operating profit and asset growth. However, revenue and net income growth are not doing good. The weighted average calculation shows that while some areas are growing, others are lagging. The company needs to focus on driving revenue and net income growth to achieve more balanced and sustainable growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 24.44 | 18.93 | 22.97 | 12.58 | -12.04 |
| Operating Profit Growth Rate | 89.66 | 52.73 | 32.14 | 6.31 | -65.25 |
| Earnings Per Share (EPS) Growth | -98.32 | -2464.58 | 60.09 | 8.15 | -79.39 |
| Asset Growth Rate | -10.19 | 10.26 | 26.86 | 8.62 | 13.21 |
| Net Income Growth Rate | -98.29 | -2400 | 100 | 8.7 | -79 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 40.87 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 7 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 10 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
| 20 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral